Pfizer Inc.
By Terry McDonald on February 23, 2011
Tags: Amyris Inc., Biomedical Sciences Investment Fund, BioProcess H2O LLC, CLARCOR Inc., CMEA Ventures, CO2 Solution Inc., Codexis Inc., CTTV Investments, FirstMark Capital, Gevo Inc., Green Plains Renewable Energy Inc., Maxygen Inc., Merck Co. Inc, NTR plc, Otter Tail Ag Enterprises LLC, Pfizer Inc., Royal Dutch Shell, Ireland, United States, USD, CO2 Solution, Codexis, Green Plains, Maxygen, Merck, Pfizer, Shell, advanced biofuels, biofuels, biopharmaceutical, business strategy, California, chemical, chemicals, diabetes treatment, energy, Finance, food, Iowa, Januvia, Lipitor, manufacturing, markets, Minnesota, Nebraska, oil, pharmaceutical, pharmaceuticals, share price, U.S. Department of Energy
Here are two very different advanced biofuel strategies: Green Plains Renewable Energy, Inc. (NASDAQ: GPRE) is producing algae from byproducts at one of its commercial ethanol plants to make biodiesel, and Codexis, Inc. (NASDAQ: CDXS) is developing biocatalysts to produce advanced biofuel and pharmaceuticals and to remove carbon from smokestacks.
